Business Context and Reporting Period
Company: cbdMD, Inc. (NYSE American: YCBD)
Reporting Period: Quarterly period ended June 30, 2025 (Fiscal Q3 2025)
Business Overview: cbdMD operates nationally recognized CBD brands (cbdMD, Paw CBD, ATRx Labs) and a THC-infused beverage line (Herbal Oasis). The company focuses on hemp-derived solutions, including broad and full-spectrum CBD products, functional mushrooms, and beverages. Operations are headquartered in Charlotte, North Carolina.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Net Sales | $4.61 million | $5.17 million | $14.47 million | $14.93 million |
| Gross Profit | $2.83 million | $3.40 million | $9.19 million | $9.54 million |
| Gross Margin | 61.5% | 65.8% | 63.5% | 63.9% |
| Operating Loss | $(0.90) million | $(0.38) million | $(1.48) million | $(3.00) million |
| Net Loss (GAAP) | $(0.90) million | $0.46 million (Income) | $(1.36) million | $(3.55) million |
| Net Loss Attributable to Common Shareholders | $(1.23) million | $(0.54) million | $(3.70) million | $(6.55) million |
| Cash and Cash Equivalents (End of Period) | $1.06 million | $2.40 million | $1.06 million | $2.40 million |
| Working Capital | $2.01 million | $(2.23) million | $2.01 million | $(2.23) million |
| Accumulated Deficit | $(179.09) million | $(182.07) million | $(179.09) million | $(182.07) million |
Note: Working capital improved significantly in Q3 2025 due to the conversion of preferred stock and elimination of accrued dividends.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 11% quarter-over-quarter (Q3 2025 vs. Q3 2024) and 3% year-to-date. Management attributes this to regulatory uncertainty impacting wholesale accounts and a temporary dip in direct-to-consumer performance.
- Equity Restructuring: On May 6, 2025, the company executed a 1-for-8 reverse stock split and converted all 5,000,000 shares of Series A Preferred Stock (plus $6.67 million in accrued dividends) into common stock. This eliminated the quarterly preferred dividend obligation and significantly improved shareholders' equity from $1.96 million (Sep 2024) to $6.11 million (Jun 2025).
- Debt Elimination: Convertible notes outstanding at September 30, 2024 ($1.17 million fair value) were fully converted into common stock during the period, resulting in zero convertible debt liability as of June 30, 2025.
- Operating Expenses: Operating expenses remained relatively flat quarter-over-quarter ($3.74 million vs. $3.79 million) but decreased $1.87 million year-to-date, driven by reduced rent (HQ office elimination) and professional fees, partially offset by increased marketing spend.
- Inventory Build: Inventory levels increased from $2.37 million (Sep 2024) to $2.80 million (Jun 2025) to address previous stock shortages caused by conservative cash management.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Strategic Focus: Management is prioritizing profitability, cost optimization, and marketing efficiency. Recent changes to the marketing team and customer acquisition funnels are showing positive trends in July 2025.
- New Product Growth: The company launched "Oasis," a THC-infused seltzer, in Q1 2025. Distribution has expanded to multiple states (AL, GA, NC, SC, FL, TN, MN), with revenue contribution expected to accelerate in Q4 2025.
- Regulatory Environment: The company faces significant regulatory headwinds at state and federal levels regarding hemp-derived products. Management is actively engaging in lobbying and compliance updates (packaging/labeling) to protect market access.
Risks and Contingencies:
- Going Concern: The filing explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern for the next 12 months. Continued operations depend on improving profitability and securing additional funding.
- Liquidity: Cash reserves of $1.06 million may be insufficient to fund daily operations for the next year without additional capital raises or improved cash flow.
- Listing Compliance: The company received a notice of non-compliance with NYSE American listing standards regarding stockholders' equity. The recent preferred stock conversion is intended to regain compliance by the December 5, 2025 deadline.
- Regulatory Risk: Potential changes in federal or state laws (e.g., redefining hemp) could materially impact revenue and product viability.
Investor Verification Checklist
- Cash Runway: Verify if the $1.06 million cash balance is sufficient to cover operating losses and preferred dividend obligations (now eliminated) for the next 12 months.
- Preferred Stock Conversion: Confirm the final share count post-conversion and the impact on dilution for existing common shareholders.
- Regulatory Status: Monitor legislative developments in key states (e.g., Texas, North Carolina, Florida) regarding hemp-derived THC and CBD products.
- Oasis Performance: Track the revenue contribution and sell-through rates of the new "Oasis" beverage line in Q4 2025.
- NYSE Compliance: Watch for updates on the company's progress toward meeting the $2.0 million stockholders' equity requirement to avoid delisting.